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In their paper, Mansour and colleagues1 have explored 
the relationship between rheumatoid arthritis (RA) and 
venous thromboembolism (VTE), an association which 
has been relatively overlooked by the existing scholar-
ly literature, despite mounting evidence suggesting a 
link between coagulation factors and pro-inflammatory 
molecules. The majority of the previous studies has em-
ployed small sample sizes, being generally statistically 
underpowered, except for few notable exceptions. Utiliz-
ing a large nation-wide database, comprising of 11,782 
patients with RA, and 57,973 age- and gender-matched 
controls, Mansour and co-workers were able to per-
form a scientifically sound and robust study, which could 
capture a significant association between RA and VTE. 
Among RA patients, VTE episodes had a rate of 6.92% 
versus 3.18% among the controls (statistically significant 
with a p-value <0.001). At the multivariate logistic regres-
sion, an odds-ratio (OR) of 2.23 (95% confidence interval 
or CI 2.05-2.43) and an OR of 1.60 (95%CI 1.44-1.78), 
both statistically significant, were computed in the model 
not adjusted for C-reactive protein (CRP) and in the mod-
el corrected for CRP, respectively. 
In a previously published systematic review of the lit-
erature and meta-analysis,2 a pooled risk ratio of 1.90 
(95%CI 1.76–2.06) of VTE episodes in RA patients had 
been found. Mansour et al.1 have replicated this finding, 
confirming the existence of such link. Taken together, 
all these results warrant the role of thromboprophylax-
is in immune mediated disorders, such as RA. Despite 
the existence of tools like the “Padua Prediction Score”, 
there is an urgent need of new validated instruments and 
scores which assess the risk of VTE episodes in hospital-
ized patients, giving more weight to current inflammatory 
rheumatologic conditions, and, therefore, potentially esti-
mating the risk of VTE in a more realistic fashion. 
In their papers, Mansour and colleagues1 have used an 
approach different from the classical one: instead of uti-
lizing a hypothesis-driven conceptual framework, they 
have relied upon data-driven techniques, including mas-
sive data mining. Real-world experiences (RWEs) mak-
ing use of real-world data (RWD) of patients treated in 
real-world settings (RWS) are emerging as a vital, integral 
component of the process of healthcare decision-mak-
ing, shaping and informing new real-world evidence 
(RWE).3,4 The use of large clinical databases and regis-
tries is paving the way for a new stratified and precision 
medicine,5 in which data-driven disease phenotyping 
and profiling play a major role.6-8 This represents an au-
thentic paradigm shift with regards to the classical “one-
size-fits-it-all” framework, favoring the rise of a personal-
ized rheumatology, in which diagnosis and treatment are 
tailored to the specific features and (biological, genetic, 
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epigenetic, and behavioral) make-up of the patient.  
Rheumatology has a long, millennial, rich tradition. Its 
history dates back to the Indian Ayurvedic physician 
Charaka (approximately 300-200 b.c.), who was an au-
thentic pioneer in the field of rheumatology. In the treatise 
“Charaka Samhita”, he described and characterized dif-
ferent clinical phenotypes of arthritis and RA (vishkantha 
in Sanskrit), whereas Hippocrates (450-380 b.c.) contrib-
uted to the diagnosis of gout and probably described 
also episodes of rheumatic fever. Galen (129-216 a.d.) 
coined the term “rheumatismus”.9-11
These descriptions and reports characterized the “pre-
history” of rheumatology (a period that we term as “rheu-
matology 1.0”), which was further advanced by the work 
of the prominent Flemish physician William Heberden 
(1710–1801), who is considered the father of the clas-
sical rheumatology (the so-called “rheumatology 2.0”). 
He was, indeed, the first physician to clinically distinguish 
between osteoarthritis (OA) and gout. In his book entitled 
“Commentaries on the history and cure of disease” he 
reported the “digitorum nodi”, which were named after 
him, being currently known as Heberden’s nodes, and 
being pathognomonic of OA.12 
The work of Heberden was preceded by the work of 
the French physician Guillaume de Baillou (also known 
as Ballonius; 1538–1616)13 and the English physician 
Thomas Sydenham (1624-1689).14 de Baillou, besides 
describing the first epidemic of pertussis, characterized 
the rheumatic fever. Sydenham described several rheu-
matologic disorders, including RA, gout, rheumatic fever, 
scorbutical rheumatism and chorea minor, which he pro-
posed to term as Saint Vitus’ dance. Other prominent 
rheumatologists were the French doctor Augustin Jacob 
Landré-Beauvais (1772-1840), who was only a 28-year-
old medical resident when, at the beginning of the XIXth 
century, he described a clinical case of RA, which is the 
first officially accepted medical record of RA.15 Alfred Gar-
rod (1819-1907), discoverer of abnormal levels of uric 
acid in the blood of gout patients, and Archibald Garrod 
(1857-1936), co-author of the “Treatise on Rheumatism 
and Rheumatoid Arthritis”, further advanced the field of 
rheumatology, contributing to the clinical diagnosis of 
RA, better specifying its diagnostic criteria. John Kent 
Spender introduced the word “osteoarthritis” in 1886,16 
or, according to some scholars, re-introduced and pop-
ularized a term coined by the German surgeon Richard 
von Volkmann (1830-1889).17 
The XIXth century has been a fervent period, rich in discov-
eries and scientific achievements. For instance, Dundas 
described rheumatic fever,18 Money the myocardial gran-
ulomas in 1883, the German physician Aschoff (1866-
1942) the nodules named after him (Aschoff’s nodules), 
whereas the association between chorea and rheumat-
ic fever was reported independently by the physicians 
Bright and See (in 1831 and in 1850, respectively).9 The 
American physician Homer Fordyce Swift (1881-1953), 
besides describing syphilis and discovering a treatment 
for cerebrospinal syphilis (which was named after him 
and Arthur Ellis) wrote extensively on the rheumatic fe-
ver and streptococcal infections. In 1928, he was able to 
link rheumatic fever with Streptococcus,19 which was lat-
er identified as causative agent by the English physician 
Collis and the American Coburn in 1931.9 One year after, 
in 1932, Todd introduced the anti-streptolysin test.20
In 1872, the Hungarian physician and dermatologist 
Moritz Kaposi (1837-1902) described the systemic na-
ture of systemic lupus erythematosus, which was later 
confirmed by the Canadian physician Osler (1849-1919) 
in 1900.9 In 1909 Nichols and Richardson were able to 
differentiate OA and RA from a clinical standpoint, dis-
tinguishing between the degenerative and proliferative 
phenotypes of arthritis.9 Some years earlier, in 1884, the 
French physician Bouchard (1837-1915) had described 
the bony outgrowths at proximal inter-phalangeal joints 
(named after him, Bouchard’s nodes), which represent a 
pathognomonic sign of OA.
The classic Reiter’s triad (comprising of reactive arthritis, 
conjunctivitis and urethritis), occurring after uro-genital 
infections or dysenteric episodes,21 has been described 
during the First World War by the German physician Hans 
Reiter (1881-1969) and, nearly contemporarily and inde-
pendently, by the French Nöel Fiessinger (1881-1946) 
and Edgar Leroy.22
Initially borne within internal medicine, rheumatology was 
recognized as a medical specialty per se with its own 
dignity (“rheumatology 3.0”), by Bernard Comroe and 
Joseph Lee Hollander (1910-2000), who coined the term 
“rheumatologist” in 1940 and co-authored the textbook 
“Arthritis and Allied Conditions”. Furthermore, Comroe 
opened the first arthritis clinics in the USA.9,23
This era is characterized by new diagnostic criteria and 
nosological definitions and classifications. For instance, 
in 1942, the concept of “connective tissue disorders” 
was introduced and developed by Paul Klemperer 
(1887-1964). In 1963, the term “ankylosing spondylitis” 
was adopted, together with the Rome’s criteria. 
At the turn of the XXth century, biological advancements 
and technological achievements have further revolution-
ized rheumatology, which could now enter the fourth 
phase (“rheumatology 4.0”),24 characterized by new so-
phisticated techniques of imaging, functional genomics 
and post-genomics specialties (proteomics, metabo-
nomics, microbiomics, among the others), the advent of 
electronic medical records (EMRs) and clinical registries, 
evidence-based medicine (EBM), with large epidemio-
logical surveys and multi-center studies, including ran-
domized controlled trials (RCTs), as well as wearable 
sensors and novel data streams (NDS, such as social 
networks and the internet-based data). Altogether this 
has provided scholars with an unprecedented wealth of 
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data (the so-called “Big Data”).25-33 
Big Data, classically characterized by 3 Vs (volume, ve-
locity and variety), are massive datasets whose size and 
volume are so large that they exceed the computational 
capacity of conventional relational database systems to 
capture, store, manage and analyze them. In the med-
ical field, Big Data can be of different types, depend-
ing on the source that generates them: they can be of 
molecular type (the so-called omics data, generated by 
high-throughput molecular assays of the latest genera-
tion), administrative (socio-economic and demographic 
data, the so-called transaction data), of instrumental/
laboratory type (M2M, known as machine-to-machine 
data), of clinical type (EMRs, and other clinical applica-
tion data) and social/behavioral (what the patient knows 
about the disease and what they search for online, the 
so-called web and social media-generated data). 
In the field of healthcare, Big Data can be used for differ-
ent purposes: including clinical epidemiology, risk predic-
tion, diagnostic and prognostic accuracy, improvement 
of the clinical outcomes, assessment of appropriateness 
of pharmacological prescriptions, and implementation 
and monitoring of the quality of the diagnostic-therapeu-
tic care, among others.
Specifically, in the field of rheumatology, Mansour and 
colleagues1 have contributed to write a new page of 
Rheumatology 4.0. In conclusion, Big Data-based rheu-
matology (“rheumatology 4.0”) appears to be a prom-
ising approach to rheumatologic diseases, even if the 
revolution has only just begun!
ACKNOWLEDGEMENTS
Giovanni Damiani is supported by the P50 AR 070590 
01A1 National Institute of Arthritis and Musculoskeletal 
and Skin Diseases, USA. 
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Mansour R, Azrielant S, Watad A, Tiosano S, Yavne Y, Comanes-
ther D, et al. Venous thromboembolism events among RA patients. 
Mediterr J Rheumatol 2019;30(1):38-43.
2. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight 
EL. Risk of venous thromboembolism in patients with rheumatoid 
arthritis: a systematic review and meta-analysis. Clin Rheumatol 
2014 Mar;33(3):297-304. [https://doi.org/10.1007/s10067-014-
2492-7] [PMId: 24424839]
3. Misra DP, Agarwal V. Real-world evidence in rheumatic diseases: 
relevance and lessons learnt. Rheumatol Int 2019 Mar;39(3):403-
416. [https://doi.org/10.1007/s00296-019-04248-1] [PMID: 
30725156]
4. Miksad RA, Abernethy AP. Harnessing the Power of Real-World 
Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data 
Quality. Clin Pharmacol Ther 2018 Feb;103(2):202-5. [https://doi.
org/10.1002/cpt.946] [PMID: 29214638] [PMCID: PMC5814721]
5. Cho SK, Sung YK. A paradigm shift in studies based on rheuma-
toid arthritis clinical registries. Korean J Intern Med 2019 Feb 18. 
[https://doi.org/10.3904/kjim.2018.440] [PMID: 30759964]
6. Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, 
Mandl T, et al. How immunological profile drives clinical phenotype 
of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 pa-
tients (Sjögren Big Data Project). Clin Exp Rheumatol 2018 May-
Jun;36 Suppl 112(3):102-12. [PMID: 30156539]
7. Schmajuk G, Yazdany J. Leveraging the electronic health record 
to improve quality and safety in rheumatology. Rheumatol Int 2017 
Oct;37(10):1603-10. [https://doi.org/10.1007/s00296-017-3804-
4] [PMID: 28852846] [PMCID: PMC5693630]
8. Cook JA, Collins GS. The rise of big clinical databases. Br J Surg 
2015 Jan;102(2):e93-e101. [https://doi.org/10.1002/bjs.9723] 
[PMID: 25627139]
9. Deshpande S. History of rheumatology. Med J DY Patil Univ 
2014;7:119-23. 
10. Entezami P, Fox DA, Clapham PJ, Chung KC. Historical perspective 
on the etiology of rheumatoid arthritis. Hand Clin 2011 Feb;27(1):1-
10. [https://doi.org/10.1016/j.hcl.2010.09.006] [PMID: 21176794] 
[PMCID: PMC3119866]
11. Sakkas LI, Tronzas P. The Greek (Hellenic) rheumatology over the 
years: from ancient to modern times. Rheumatol Int 2019, in press. 
[https://doi.org/10.1007/s00296-019-04261-4]
12. Joshi VR, Poojary VB. William Heberden (elder) (1710-1801). J As-
soc Physicians India 2013 Dec;61(12):946-7. [PMID: 24968564]
13. Baruch JZ. [Guillaume de Baillou, precursor of modern rheumatol-
ogy. Some biographical data with contemplations]. Ned Tijdschr 
Geneeskd 1965 Oct 30;109(44):2086-91. [PMID: 5321429]
14. Stochik AM, Zatravkin SN. [The contribution of T. Sydenham 
(1624-1689) to the formation of modern Western medicine (on 
the occasion of the 390th anniversary of his birth)]. Ter Arkh 
2014;86(8):138-42. [PMID: 25306762]
15. Landré-Beauvais AJ. The first description of rheumatoid arthritis. 
Unabridged text of the doctoral dissertation presented in 1800. 
Joint Bone Spine 2001 Mar;68(2):130-43. [PMID: 11324929]
16. Spender JK. On some Hitherto Undescribed Symptoms in the 
Early History of Osteoarthritis. The So-Called Rheumatoid Arthritis. 
Br Med J 1888 Apr 14;1(1424):781-3. [PMID: 20752255] [PMCID: 
PMC2197518]
17. Dobson GP, Letson HL, Grant A, McEwen P, Hazratwala K, Wilkin-
son M, et al. Defining the osteoarthritis patient: back to the fu-
ture. Osteoarthritis Cartilage 2018 Aug;26(8):1003-7. [https://doi.
org/10.1016/j.joca.2018.04.018] [PMID: 29775734]
18. Dundas D. An account of a peculiar Disease of the Heart. Med Chir 
Trans 1809;1:37-46. [PMID: 20895121] [PMCID: PMC2128801]
19. Dochez AR. Homer Fordyce Swift, 1881-1953. Trans Assoc Am 
Physicians 1954;67:25-7. [PMID: 13216807]
20. Lawy HS. Use and interpretation of the antistreptolysin test. 
Ann Rheum Dis. 1960;19:42-7. [PMID: 14414765] [PMCID: 
PMC1007358]
21. Wu IB, Schwartz RA. Reiter’s syndrome: the classic triad and 
more. J Am Acad Dermatol 2008 Jul;59(1):113-21. [https://doi.
org/10.1016/j.jaad.2008.02.047] [PMID: 18436339]
22. Pasero G, Marson P. [Wars in the history of rheumatology]. Reuma-
tismo 2007 Oct-Dec;59(4):332-7. [PMID: 18157291]
23. Benedek TG. History of Rheumatic Diseases. In: (J.H. Klippel, Ed.) 
“Primer on the Rheumatic diseases”. Atlanta, Arthritis Foundation, 
1997;11:1–5. 
24. Burmester GR. Rheumatology 4.0: big data, wearables and diag-
nosis by computer. Ann Rheum Dis 2018 Jul;77(7):963-5. [https://
doi.org/10.1136/annrheumdis-2017-212888] [PMID: 29802224] 
[PMCID: PMC6029631]
25. Burmester GR, Häupl T. Big data-also relevant in rheumatology? Z 
Rheumatol. 2018 Apr;77(3):192-4.
26. Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos 
AA, Kitas GD, et al. Biologic treatment for rheumatic disease: re-
al-world big data analysis from the Greek country-wide prescription 
database. Clin Exp Rheumatol 2017 Jul-Aug;35(4):579-85. [PMID: 
28281458]







Theander E, et al. Influence of geolocation and ethnicity on the 
phenotypic expression of primary Sjögren’s syndrome at diagnosis 
in 8310 patients: a cross-sectional study from the Big Data Sjögren 
Project Consortium. Ann Rheum Dis 2017 Jun;76(6):1042-50. 
[https://doi.org/10.1136/annrheumdis-2016-209952] [PMID: 
27899373]
28. Symmons DP. Epidemiology research in rheumatology-progress 
and pitfalls. Nat Rev Rheumatol 2015 Nov;11(11):631-8. [https://
doi.org/10.1038/nrrheum.2015.92] [PMID: 26150125]
29. Gonzalez A, Valdes AM. Big data boost for osteoarthritis ge-
netics. Nat Rev Rheumatol 2018 Jul;14(7):387-88. [https://doi.
org/10.1038/s41584-018-0023-7] [PMID: 29899548]
30. Landewé RBM, van der Heijde D. “Big Data” in Rheumatology: 
Intelligent Data Modeling Improves the Quality of Imaging Data. 
Rheum Dis Clin North Am 2018 May;44(2):307-15. [https://doi.
org/10.1016/j.rdc.2018.01.007] [PMID: 29622297]
31. Winter DR. Thinking BIG rheumatology: how to make functional ge-
nomics data work for you. Arthritis Res Ther 2018 Feb 12;20(1):29. 
[https://doi.org/10.1186/s13075-017-1504-9] [PMID: 29433549] 
[PMCID: PMC5810031]
32. Ramos-Casals M, Brito-Zerón P, Kostov B, Sisó-Almirall A, Bosch 
X, Buss D, et al. Google-driven search for big data in autoimmune 
geoepidemiology: analysis of 394,827 patients with systemic auto-
immune diseases. Autoimmun Rev 2015 Aug;14(8):670-9. [https://
doi.org/10.1016/j.autrev.2015.03.008] [PMID: 25842074]
33. Bragazzi NL, Watad A, Brigo F, Adawi M, Amital H, Shoenfeld Y. 
Public health awareness of autoimmune diseases after the death 
of a celebrity. Clin Rheumatol 2017 Aug;36(8):1911-7. [https://doi.
org/10.1007/s10067-016-3513-5] [PMID: 28000011]
